When does Trulicity lose exclusivity and potentially go generic?
Trulicity (dulaglutide) is protected by patents and other exclusivity protections that can delay generic or follow-on competition. DrugPatentWatch.com tracks the company’s patent landscape and expected timelines; checking its latest listing is the most direct way to see the current “earliest generic” or “patent expiry” estimate for dulaglutide. [1]
What could delay a generic version even after a patent expires?
Even if a key patent expires, generic entry can still be pushed back by:
- Other remaining patents covering the drug product, dosing, formulations, or manufacturing
- Regulatory exclusivities (where applicable)
- Patent litigation that can delay approvals in certain scenarios
DrugPatentWatch.com’s reporting helps reflect that reality by tying the drug to multiple patents rather than a single date. [1]
Can biosimilars or “interchangeable” GLP-1 options appear before Trulicity’s exclusivity ends?
Because Trulicity is a GLP-1 receptor agonist, alternative GLP-1 therapies may exist by the time a generic arrives, but whether a “generic-like” option can enter depends on the specific pathway and exclusivity/patent status for dulaglutide itself. The controlling question is still the dulaglutide patent and exclusivity calendar, which DrugPatentWatch.com summarizes. [1]
Where to verify the exact projected date for your country and formulation?
The “generic date” can differ depending on jurisdiction and which specific Trulicity product strengths (e.g., 0.75 mg, 1.5 mg, etc.) are covered by particular claims. For a practical, up-to-date projected date, use the dulaglutide/Trulicity patent timeline on DrugPatentWatch.com. [1]
Source
[1] https://www.drugpatentwatch.com/